Combining the NMP22 Bladderchek urine test with cystoscopy can detect bladder cancer in its early stages, with 99 per cent detection rates.
Inverness Medical's NMP22 Bladderchek assay measures the nuclear matrix protein NMP22 in voided urine and increases the detection of new and recurrent bladder tumours.
Studies have demonstrated that the NMP22 test can identify several malignancies missed by initial cystoscopy, with increased combined sensitivity of 99 per cent.
It is also an ideal marker for monitoring patients with existing bladder cancers and for detecting recurrences earlier.
The NMP22 Bladderchek test can provide immediate results.
The assay is painless and non-invasive and removes the need for expert analysis or laboratory time.
The presence of blood in the sample, one of the first symptoms of bladder cancer, does not interfere with the NMP22 Bladderchek results.
The NMP22 Bladderchek test needs only four drops of urine and is ideal for initial assessment and monitoring.
The rapid format of the NMP22 Bladderchek test can facilitate the screening of at risk groups such as smokers, fire fighters, petro-chemical workers, hairdressers, painters, textile workers, road construction workers (tar) and arson investigators.
As with many types of cancer, the outcome of bladder cancer depends on how advanced it is when it is diagnosed.
Therefore, early detection while the tumour is still at a superficial stage is extremely important and can be aided with the introduction of urinary marker tests in conjunction with cystoscopy.
